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Development of efficient commercial process for the preparation of highly pure 4'-(2-Butyl-4-oxo-1,3-diaza-
spiro[4,4]non-1-en-3-ylmethyl)-biphenyl-2-carbonitrile (1), an advanced intermediate of Irbesartan is described.  
The developed process minimizes the impurity formation and utilizes the simplified process to improve yield, 
throughput and is suitable for production on commercial scale. 
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INTRODUCTION 
Irbesartan (Figure 1) is a non-peptide angiotensin II receptor antagonist useful in the management of 
hypertension, heart diseases, heart strokes, diabetic neuropathy and congestive heart diseases
1
.  Irbesartan 
is currently available in the market as an antihypertensive drug under the brand name of Avapro
2
. 
Generally, Angiotensin II receptor blockers (ARBs) such as Irbesartan bind to the Angiotensin II type 1 
(AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth 
muscle, ultimately leading to reduction in arterial blood pressure.  The metabolism of Irbesartan, a highly 





Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective noncompetitive antagonism of 
the AII receptor subtype 1 (AT1) which mediates most of the known physiological activities of AII
4
.  
The angiotensin II type 1 (AT1) receptor plays a pivotal role in the regulation of blood pressure and 
electrolyte balance, and is involved in the control of specific ingestive behaviours. Irbesartan is a recently 




The first reported synthetic method
6,7
 as shown in scheme-1
 
for the preparation of advanced intermediate 
(1) of Irbesartan consists of the condensation of 4'-Bromomethyl-biphenyl-2-carbonitrile (3) with 2-
Butyl-1,3-diaza-spiro[4,4]non-1-en-4-one hydrochloride (4) using sodium hydride (NaH) as a base and 
dimethyl formamide (DMF) as solvent medium. When NaH is used as base in the process, utmost care 
should be taken to perform the reaction under inert atmosphere as it is an exothermic reaction, highly 
sensitive towards moisture, it is unsafe and not suitable for production on commercial scale.  The DMF is 
readily bioabsorbed through the skin, highly irritant to skin and mucous membrane. Removal of high 
boiling solvents like DMF in the process is difficult and not economic.  Moreover the product was 
purified through column chromatography which is not commercially viable and the reported reagent and 
solvent were not suitable for the large scale production. 
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Scheme-1:  Reagents & conditions a) NaH, DMF, room temperature 
 
 
Another procedure was described in the literature, as per which the condensation was performed in 
toluene and DMF mixture using different bases like sodium methoxide, sodium hydroxide, cesium 




As per the process described in the patent, the condensation was performed using 
methyltributylammonium chloride as phase transfer catalyst in toluene as well as dichloromethane in the 
presence of different concentrations of aqueous sodium hydroxide. The drawbacks of these methods are 
multiple extractions, acid base treatment, lengthy and tedious isolation procedures
9
. 
A more recent procedure was disclosed in the literature in which the N-alkylation for the preparation of 
Irbesartan intermediate (1) was carried out in three steps
10
. These steps involve a) free base preparation of 
2-Butyl-1,3-diaza-spiro[4,4]non-1-en-4-one hydrochloride (4) from its hydrochloride salt b) condensation 
with 4'-Bromomethyl-biphenyl-2-carbonitrile (3) using potassium carbonate/ potassium hydroxide in 
acetone medium c) purification of the crude residue in ethylacetate and n-hexane mixture to obtain the 
required product with the purity of ~98% and the yield of ~80%.  
An improved process was disclosed in WO publication
 
as per which the condensation reaction was 
performed in DMF medium using sodium hydroxide as base. As DMF is high boiling and water miscible 
solvent and considering the recovery and reuse aspects, it is not suitable on commercial scale. Moreover 
the process does not mention the impurity profile
11
.  
The process disclosed in our manuscript is affording the product with higher yield and purities than the 
reported processes with all potential impurities (Figure 2) in control. 
An analogous synthetic approach for the preparation of 4'-(2-Butyl-4-oxo-1,3-diaza-spiro[4,4]non-1-en-3-
ylmethyl)-biphenyl-2-carbonitrile hydrochloride is reported in the literature
12
 which involves the 
condensation of the compound 4 with compound 3, which is having different ratios of dibromo and 
tribromo compounds. The reaction was carried out in the presence of diethyl phosphate as a reducing 
agent along with potassium hydroxide as a base in biphasic medium and Methyl tributyl ammonium 
chloride (MTBAC) as a phase transfer catalyst.  However, the purity of the obtained in the above process 
for the intermediate is not mentioned.  This process suffers from the disadvantages like use of expensive 
reducing agents and requires the purification of the crude product in mixture of solvents.  There is no 
control on the formation of impurities for bromination of the intermediate.  
Therefore, there is a need to have the process to produce high pure Irbesartan Intermediate (1) as it will 
impact on the yield and purity of the finished product. Herein, we report an economic, efficient and 
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EXPERIMENTAL 





were recorded in CDCl3 using a Bruker 400 MHz spectrometer. The chemical shift data was reported as δ 
(ppm) downfield from tetramethylsilane, which is used as an internal standard. The mass spectra were 
recorded using an HP 5989A LC-MS spectrometer. The FT-IR spectra were recorded in the solid state as 
a KBr dispersion using a Perkin-Elmer 1650 FT-IR spectrophotometer.  The chromatographic purity of 
the compounds was analyzed using Agilent 1200 series HPLC instrument under the following conditions: 
Column      : Symmetry C18, 4.6 × 75 mm, 3.5 µm  
Mobile phase    :   Eluent A:  Deionized water, Eluent B: HPLC grade Methanol 
 
Chromatographic Conditions 
a. Column temperature : Ambient 
b. Sample compartment  : Ambient  
c. Detector  : 225 nm 
d. Injection volume  : 10 µL 
e. Run time   : 45 minutes  
f. Flow rate              :1.0 mL/min 
g. Injector   :Auto sampler with variable volume injector    
h. Diluent               : HPLC grade Acetonitrile 
 
4'-Bromomethyl-biphenyl-2-carbonitrile (3) 
To a solution of compound 2 (100 g, 0.517 moles) in acetonitrile (500 mL) was added 1,3-dibromo-5,5-
dimethylhydrantoin (DBDMH, 107.2 g, 0.72 moles) and 2,2’-Azobiisobutyronitrile (AIBN, 0.85 g, 0.005 
moles).  The contents were heated to reflux and maintained for 5-6 hours.  Reaction progress could be 
monitored using Thin Layer Chromatography (TLC).   After completion of the reaction, the solvent was 
distilled off, added water (500 mL) into the reaction mixture and maintained under stirring for 1 hour.  
The reaction mixture was cooled to 25-30°C and further maintained under stirring for 1 hour.  Filtered the 
solid and washed with water (100 mL).  To the wet compound, isopropanol (100 mL) was added and 
stirred for 1 hour at 25-30°C. Filtration followed by drying at 60-70°C afforded the title compound as a 
crystalline solid. Yield: 132 g, 93%. IR (KBr, cm
-1
): 2220.71 (CN stretching), 1593.92,1560 (C=C 




H-NMR (CDCl3) δ 4.56 (2H, 
s), 7.42-7.67 (3H, m), 7.52 (4H, s), 7.78 (1H, d, J=7 Hz). 
4'-(2-Butyl-4-oxo-1, 3-diaza-spiro [4.4] non-1-en-3-ylmethyl)-biphenyl-2-carbonitrile (1) 
To a solution of compound 4 (445 g, 1.93 moles) in dichloromethane (2500 mL) was added Triethyl 
benzyl ammonium chloride (13.18 g, 0.058 moles) under stirring. The contents were cooled to 5
o
C and 
aqueous solution of KOH (410 g, 7.32 moles, was dissolved in 880 mL of water) was added slowly 
during 30 minutes. Compound 3 (500 g, 1.83 moles) was added and reaction mixture was allowed to 
reach 25
o
C and maintained for 45 minutes. The completion of the reaction was confirmed by TLC, added 
water (2500 mL) by keeping the temperature at below 30°C and stirred for 20 minutes. The organic layer 
was separated, washed with water (1000 mL) followed brine solution (1000 mL) and dried over 
anhydrous sodium sulphate (50 g). The solvent was evaporated under vacuum to obtain crude product. 
The mixture of isopropanol (800 mL) and water (1200 mL) was added to the crude product, stirred for 1.5 
hours at room temperature and stirred at 0-5
o
C for 30-45 minutes. The product was filtered and washed 
with the mixture of isopropanol (200 mL) and water (300 mL). The wet product was dried under vacuum 
at 40-45
o
C for 6 hours. Yield: 0.673 Kg, 95.4 %; IR (KBr, cm
-1
): 2220.72 (CN stretching), 1720.08 (C=O 
amide stretching), 1628.73 (C=N stretching);  Mass: HRMS(ES
+
) calculated for C25 H28N3O (M+H)
+
 : 
386.22269, observed value : 386.22218 ; 
1
H-NMR (CDCl3) δ 7.77 (d, J=7.6 Hz, 1H), 7.65 (td, J=1.1, 
J=7.7 Hz,1H), 7.54 (J=4.1 Hz, 2H), 7.49 (d, J=7.6Hz, 1H), 7.45 (d, J=7.7 Hz, 1H), 7.28 (d, J=8.10Hz, 
2H), 4.75 (s, 2H), 2.35 (t, J=7.8 Hz, 2H), 2.06-1.93 (m, 6H), 1.88-1.84 (m, 2H), 1.60 (quintet, J=7.4 Hz, 
2H), 1.34 (sextet, J=7.4 Hz, 2H), 0.88 (t, J=7.3 Hz, 3H);  
13
C-NMR (CDCl3) δ 186.8, 161.5, 144.7, 137.7, 
137.2, 133.8, 132.9,132.0, 129.4, 127.7, 127.1, 118.6, 111.2, 76.6, 43.3, 37.5,  28.8, 27.8, 26.1, 22.3, 13.7.    
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RESULTS AND DISCUSSION 
In our improved process, as shown in scheme-2, we explored the possibility of using commercially 
available 2-Butyl-1,3-diaza-spiro[4,4]non-1-en-4-one hydrochloride and 4'-methyl-biphenyl-2-
carbonitrile as the intermediates for the preparation of 4'-(2-Butyl-4-oxo-1,3-diaza-spiro[4,4]non-1-en-3-


















Scheme-2: Reagents & conditions a) DBDMH/AIBN, acetonitrile and isopropanol b) KOH, dichloromethane, 
TEBAC, isopropanol and water. 
 
Synthesis of 4'-bromomethyl-biphenyl-2-carbonitrile (3) 
The reported processes 
12
 for the bromination using sodium bromate and aqueous hydrobromic acid gave 
different ratios of by products ranging from 10-20% under photolytic conditions.  Diethyl phosphate is 
used as a reducing agent for the reduction of the dibromo and tribromo impurities formed in the process.  
The obtained crude is preceded to further stage without isolation of the product which is having different 
ratios of the impurities in the residue, which may effect on the yield and purity of the intermediates. We 
attempted to carry out the bromination with N-bromosuccinamide (NBS) using dibenzoyl peroxide as free 
radical initiator in different solvent mediums like carbon tetrachloride, chloroform, dichloromethane and 
acetonitrile. The product obtained with the yield of 70-80% and dibromo impurity formation was 
observed in each case.  
To overcome these problems, we have chosen DBDMH (1,3-dibromo-5,5-dimethyl hydrantoin) as a 
reagent in the presence of AIBN ( 2,2’-Azobiisobutyronitrile) as a free radical initiator for bromination to 
minimize the formation of dibromo and tribromo impurities in the process.  We have studied the effect of 
DBDMH equivalents and the solvent medium for this transformation (chloroform, dichloromethane, 
acetonitrile and ethyl acetate). The product was obtained with optimum yield and quality (dibromo 
impurity <0.5%) when DBDMH was used with 0.72 eq. and acetonitrile was used as solvent medium.   
 
Condensation of 4'-bromomethyl-biphenyl-2-carbonitrile (3) and 2-Butyl-1, 3-diazaspiro [4, 4] non-
1-en-4-one (4) 
To improve the yield and quality of the desired product 1, extensive optimization studies were taken up 
by the screening of reagents, solvents and reaction parameters. As per the basic patent route 
6
, sodium 
hydride was used to effect the transformation of compound 3 to compound 1. Considering the cost factor 
and hazardous nature of the employed base (NaH) in combination with DMF, we intended to screen non-
toxic and inexpensive bases in combination with different solvents to effect the transformation in an 
efficient manner.  Among the screened bases, potassium hydroxide with dichloromethane indicated the 
best results.  The data has been provided in the Table 1. 
To find out the cumulative effect of the base and solvent on transformation in terms of yield and quality 
we optimized the base equivalents in the presence of dichloromethane quantity as 5.0 volumes. It turned 
out that 6.0 eq. of KOH is required for 1 mol of compound 3 (Table 2). 
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As the compound 4 is insoluble in dichloromethane, it required water in the reaction along with 
dichloromethane. The quantity of the water which plays a prominent role in the biphasic reaction was also 
optimized. The reaction homogeneity and better conversion was observed with 1.76 volumes of water 
with respect to compound 3.  
It is well established fact that the temperature of the reaction plays the crucial role in the conversion of the 
starting material to the product. By keeping the other factors constant, we optimized the temperature of 
the reaction. It was observed that the optimum conversion without the side reaction can be achieved at 20-
25
o
C (Table 3).   
In this transformation, the phase transfer catalyst plays the pivotal role. For this we have screened 
tetrabutyl ammonium bromide (TBAB), methyl tributyl ammonium chloride (MTBAC), triethyl benzyl 
ammonium chloride (TEBAC) and tetrabutyl ammonium chloride (TBAC) among which TEBAC has 
shown the superior results. 
Once the highest conversion of the reaction was achieved in the optimized conditions (based on the HPLC 
purity of the reaction mass), different purification trials were attempted and a robust in situ purification 
method has been developed to remove all the impurities in the process by using isopropanol and water 
mixture as a medium for crystallization of the crude product. The purification trials details are provided in 
Table 4. The isopropanol and water mixture in 2:3 ratio was observed to be optimum to obtain the product 
with high purity with minimum yield loss. 
After these systematic optimization studies, our attempts for the condensation of 2-Butyl-1, 3-diaza-spiro 
[4, 4] non-1-en-4-one hydrochloride (4) with bromo compound (3) was successful in affording the 
product (1) with high yield (95%) with all the possible potential impurities in control. Thus the process 
for the condensation of compound 3 and compound 4 was established by using potassium hydroxide as a 
base in dichloromethane and water mixture. TEBAC was used as phase transfer catalyst. The product was 
isolated by the insitu crystallization in isopropanol and water mixture. The present process produced the 
Irbesartan intermediate in high pure form (99.9%) with high yields (95%). The consistency and 
reproducibility were checked by performing the experiments on 500 g scale, the yields and purities are 
consistent and the data has been furnished in Table 5. 
During the optimization studies and the screening of the various parameters, we have observed some 
impurities formation. These were identified by LCMS, isolated from the mother liquors and purified 
through different techniques like column chromatography, solvent washings and crystallizations. Total six 
impurities were identified and characterized by the spectroscopic methods (one of them is the starting 
material, 4 and another one is the intermediate, compound 3). The impurities structures are shown in 
Figure 2 and synthetic schemes have been provided in Scheme-3. All these impurities were efficiently 
controlled in our improved process (Table 5). 
 
CONCLUSION 
In conclusion, we have established the optimized conditions for the bromination on compound 2 and 
systematically studied the effect of base, catalyst, solvent volume and temperature for the condensation of 
compound 3 with compound 4. We have developed an improved, high yielding, eco friendly and 
industrially feasible process for Irbesartan intermediate with all the potential impurity levels in control. 
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Fig.-1: Structure of Irbesartan 
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Fig.-2: Structures of impurities 
 












01 Sodium hydroxide DMF 25-30
o
C 6 hours 62.9% 94.5% 




C 2.2 hours 85.7% 96.3% 




C 1.5 hours 80.1% 99.2% 
04 Potassium carbonate DMF 40-45
o
C 8.5 hours 73.7% 93.1% 
05 Potassium carbonate Toluene + water 91-95
o
C 15 hours 77.6% 98.17% 
06 Cesium carbonate DMF 25-30
o
C 4.5 hours 74.5% 94.3% 
07 Sodium methoxide DMF 25-30
o
C 2.5 hours 72% 95.3% 




C 1.5 hours 6.3.7% 93.7% 
06 Potassium Hydroxide Dichloro 
methane + water 
25-30
o
C 45 min 95.3% 99.9% 
 
















01 2.0 10 hours 25-30
o
C -- -- Reaction was not proceeded for 
completion. ~45% conversion 
observed by HPLC 
02 4.0 6 hours 25-30
o
C -- -- Reaction was not proceeded for 
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completion. ~75% conversion 
observed by HPLC 
03 6.0 45 min 25-30
o
C 95% 99.8% Reaction was proceeded for 
completion. 
04 8.0 30 min 25-30
o




Table-3: Effect of temperature on the reaction progress 
 
 
Table-4: Effect of isopropanol and water ratio on yield and quality 
 
Expt No Isopropanol  
: water  
Yield  
(%) 
Purity by  
HPLC (%) 
01 0:5 98.1 96.5 
02 1:4 97.3 99.05 
03 2:3 95 99.95 
04 3:2 93 99.95 
 
 
Table-5: Yield and purities data for the purification in mixture  of isopropanol and water 
 







Imp-A Imp-B Imp-C Imp-D Imp-E Imp-F 
01 95.4 99.95 0.01 ND 0.01 ND ND ND 
02 96.0 99.93 0.03 ND 0.02 ND ND ND 
03 94.8 99.95 0.01 ND 0.01 ND ND ND 
  
* ND= Not detectable 
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C 45 min 95.2% 99.87% Reaction was proceeded for completion. 
04 40-45
o
C 30 min 92.7% 98.1% Reaction was proceeded for completion. 
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